In chapter nineteen, Kaneda et al. develop a hemagglutinating virus of Japan envelope (HVJ-E) vector using inactivated Sendai virus, as a pseudovirion for gene and drug delivery. They evaluate the anti-tumor effects of HVJ-E itself on mouse and human melanoma in animal models, and also the enhancement of anti-tumor effects of HVJ-E containing IL-12 gene. The last chapter reviews the pharmacokinetic study of viral vectors for gene therapy, including pharmacokinetic characteristics of viral vectors, analysis methods used for pharmacokinetic evaluations of viral vectors, and challenges and prospects